Filing Flows › Maxcyte (MXCT) › Next earnings date
Maxcyte (MXCT) earnings on Nov 10, 2026: what to expect
Maxcyte (MXCT) is expected to report earnings on Nov 10, 2026, in 2 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.08 (−$0.09 to −$0.08, 3 estimates) on revenue of $7.5M, against −$0.09 and $6.8M a year ago. It beat the EPS estimate in 100% of the quarters on record; Filing Flows' model gives it a 85% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.09 on revenue of $6.2M, against the analysts' −$0.08.
The last report
Maxcyte reported revenue of $7.3M for the second quarter 2026 (-14% Y/Y), net loss $8.9M: Product sales $4.1M, Licenses $2.6M, Assay and other service revenue $583K. How it makes money → · Every quarter →
Maxcyte's latest quarter
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
When does MXCT report earnings?
Maxcyte is expected to report on Nov 10, 2026.
What are analysts expecting from Maxcyte?
EPS of −$0.08 and revenue of $7.5M for the quarter.
Does Maxcyte usually beat earnings?
It beat the consensus EPS estimate in 100% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.